Streamlining screening to treatment: The Hepatitis C cascade of care at Kaiser Permanente Mid-Atlantic States

Clinical Infectious Diseases

Volumn 62, Issue 10, 2016, Pages 1290-1296

  Jonas, M Cabell ^a   Rodriguez, Carla V ^b   Redd, Jacquelyn ^a   Sloane, Dana A ^a   Winston, Bradley J ^a   Loftus, Bernadette C ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b Mid Atlantic Permanente Research Institute   (United States)

Author keywords

cascade of care; HCV; hepatitis C virus; linkage to care; screening

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS C; ELASTOGRAPHY; ELECTRONIC HEALTH RECORD; FEMALE; HEALTH INSURANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; PRIORITY JOURNAL; SCREENING; VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY; AGED; BLOOD; COHORT ANALYSIS; DIAGNOSTIC IMAGING; GENETICS; HEPACIVIRUS; IMMUNOLOGY; LIVER CIRRHOSIS; MASS SCREENING; PROCEDURES; UNITED STATES; VIROLOGY;

AGED; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; LIVER CIRRHOSIS; MALE; MASS SCREENING; MID-ATLANTIC REGION; MIDDLE AGED;

EID: 84966331066     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw086     Document Type: Article

References (35)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144: 705-14.
2. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012; 55: 1652-61.
3. Ward JW. The epidemiology of chronic hepatitis C and one-Time hepatitis C virus testing of persons born during 1945 to 1965 in the United States. Clin Liver Dis. 2013; 17: 1-11.
4. Xu F, Tong X, Leidner AJ. Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase. Health Aff. 2014; 33: 1728-35.
5. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368: 1878-87.
6. Clark EC, Yawn BP, Galliher JM, Temte JL, Hickner J. Hepatitis C identification and management by family physicians. Fam Med. 2005; 37: 644-9.
7. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405-16.
8. Committee on the Prevention and Control of Viral Hepatitis Infection; Board on Population Health and Public Health Practice; Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Colvin HM, Mitchell AE, eds. Washington, DC: National Academies Press, 2010.
9. Leverence RR, Williams RL, Pace W, et al. Context of clinical care: the case of hepatitis C in underserved communities-A report from the Primary Care Multiethnic Network (PRIME Net) Consortium. J Am Board Fam Med. 2009; 22: 638-46.
10. Moorman AC, Gordon SC, Rupp LB, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study. Clin Infect Dis. 2013; 56: 40-50.
11. Highleyman L. Hepatitis C cascade studies show gaps in testing and treatment. Available at: http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-Topics/hcvtreatment/.4693-hepatitis-c-cascade-studies-show-gaps-in-Testing-And-Treatment. Accessed 10 May 2015.
12. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013; 368: 1859-61.
13. Graham CS. Hepatitis C and HIV co-infection: closing the gaps. JAMA. 2015; 313: 1217-8.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 958-65.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975-82.
16. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-Alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140: 346-55.
17. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36(5 suppl 1): S237-44.
18. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014; 384: 1756-65.
19. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368: 1867-77.
20. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1483-93.
21. Linas BP, Hu H, Barter DM, Horberg M. Hepatitis C screening trends in a large integrated health system. Am J Med. 2014; 127: 398-405.
22. Rodriguez CV, Hu H, Rubenstein K, Linus BMH. Increasing hepatitis C virus (HCV) screening and confirmatory testing in a large integrated health system. In: 2015 National Summit on HCV and HIV, Arlington, VA, June 2015.
23. Chen C, Garrido T, Chock D, Okawa G, Liang L. The Kaiser Permanente electronic health record: transforming and streamlining modalities of care. Health Aff. 2009; 28: 323-33.
24. Maryland Health General Code. 18-202.1. Available at: http://mgaleg.maryland. gov/webmga/frmStatutesText.aspx?article=ghg§ion=18-202.1&ext=html &session=2015S&tab=subject5. Accessed 25 February 2016.
25. Code of Virginia, Title 32.1 Health. 32.1-37.2. Available at: http://law.lis.virginia. gov/vacode/32.1-37.2/. Accessed 25 February 2016.
26. Centers for Disease Control and Prevention. State HIV laws. Available at: http://.www.cdc.gov/hiv/policies/law/states/index.html#DC. Accessed 25 February 2016.
27. Horberg M, Hurley L, Towner W, et al. HIV quality performance measures in a large integrated health care system. AIDS Patient Care STDS. 2011; 25: 21-8.
28. Horberg MA, Hurley LB, Towner WJ, et al. Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2012; 60: 183-90.
29. Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014; 16: 372.
30. Cha SW, Jeong WK, Kim Y, et al. Nondiseased liver stiffness measured by shear wave elastography: a pilot study. J Ultrasound Med. 2014; 33: 53-60.
31. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011; 53: 325-35.
32. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46: 32-6.
33. American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62: 932-54.
34. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009; 16: 36-44.
35. Somashekhar S. Costly hepatitis drug Sovaldi rattles industry. Available at: http://.www.washingtonpost.com/national/health-science/costly-hepatitis-drug-sovaldirattles-industry/2014/03/01/86cab0b4-A091-11e3-9ba6-800d119208b-story. html. Accessed 25 February 2016.